Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00251576 | Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) | PHASE3 | COMPLETED | 4,497 | — | — | Nov 1, 1999 | Mar 23, 2004 | Aug 15, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| A-Phase: tirofiban; Z-Phase simvastatin | DRUG | - |
| Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years | DRUG | - |
| Comparator: A-Phase: low molecular weight heparin, unfractionated heparin | DRUG | - |
| Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours | DRUG | - |
| Duration of Treatment: Z-Phase, 2 years. | DRUG | - |
Inclusion Criteria: * A-Phase: Chest pain at rest for 10 minutes, EKG changes or elevated cardiac blood work * Z-Phase: elevated cholesterol , plus at least one risk factor ( \> 70 years old, diabetes, history of prior heart or blood vessel disease, chest pain with EKG changes, elevation of cardiac...